AGIOS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.49 USD | -0.57% |
|
+6.64% | +41.40% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,265 | 3,001 | 1,785 | 1,543 | 1,245 | 1,788 | - | - |
| Enterprise Value (EV) 1 | 3,184 | 2,690 | 1,582 | 1,421 | 1,215 | 1,719 | 1,824 | 1,675 |
| P/E ratio | -6.96 x | -9.14 x | 1.24 x | -6.64 x | -3.52 x | -5.75 x | -5.35 x | -7.06 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 27.7 x | 14.8 x | - | 108 x | 46.4 x | 42.3 x | 15.7 x | 9.05 x |
| EV / Revenue | 27 x | 13.2 x | - | 99.8 x | 45.3 x | 40.7 x | 16 x | 8.48 x |
| EV / EBITDA | -7.61 x | -8.79 x | -4.29 x | -3.73 x | -3.16 x | -5.1 x | -4.47 x | -4.69 x |
| EV / FCF | -8.32 x | -8.8 x | -3.83 x | -4.52 x | -4.09 x | -5.12 x | -7.37 x | -7.15 x |
| FCF Yield | -12% | -11.4% | -26.1% | -22.1% | -24.5% | -19.5% | -13.6% | -14% |
| Price to Book | 4.47 x | 7.48 x | 1.54 x | 1.4 x | 1.53 x | 2.52 x | 2.75 x | 3.4 x |
| Nbr of stocks (in thousands) | 68,371 | 69,260 | 54,308 | 54,945 | 55,891 | 56,773 | - | - |
| Reference price 2 | 47.75 | 43.33 | 32.87 | 28.08 | 22.27 | 31.49 | 31.49 | 31.49 |
| Announcement Date | 20-02-13 | 21-02-25 | 22-02-24 | 23-02-23 | 24-02-15 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 117.9 | 203.2 | - | 14.24 | 26.82 | 42.22 | 113.7 | 197.5 |
| EBITDA 1 | -418.2 | -306.2 | -369.2 | -380.5 | -384.9 | -337.3 | -408.3 | -357 |
| EBIT 1 | -426.3 | -316.1 | -378.4 | -389 | -391.5 | -379.1 | -371.5 | -315.2 |
| Operating Margin | -361.57% | -155.59% | - | -2,732.07% | -1,459.52% | -898.05% | -326.64% | -159.56% |
| Earnings before Tax (EBT) 1 | -411.5 | -327.4 | -356.5 | -231.8 | -352.1 | -284.3 | -323.6 | -255.3 |
| Net income 1 | -411.5 | -327.4 | 1,605 | -231.8 | -352.1 | -318.2 | -361 | -299.9 |
| Net margin | -348.97% | -161.11% | - | -1,627.82% | -1,312.63% | -753.65% | -317.41% | -151.82% |
| EPS 2 | -6.860 | -4.740 | 26.55 | -4.230 | -6.330 | -5.479 | -5.886 | -4.459 |
| Free Cash Flow 1 | -382.8 | -305.7 | -413.1 | -314.4 | -297.1 | -335.7 | -247.5 | -234.4 |
| FCF margin | -324.64% | -150.43% | - | -2,207.58% | -1,107.49% | -795.22% | -217.57% | -118.68% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-13 | 21-02-25 | 22-02-24 | 23-02-23 | 24-02-15 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.832 | 5.582 | 3.516 | 4.31 | 5.609 | 6.712 | 7.399 | 7.103 | 8.372 | 9.508 | 11.14 | 12.72 | 38.16 |
| EBITDA 1 | -88.94 | - | - | - | - | - | -88.82 | -91.89 | - | -104.9 | -100 | -99 | -100 | 100 | - |
| EBIT 1 | -91.15 | -104.8 | -101.1 | -97.64 | -91.09 | -99.17 | -90.61 | -93.7 | -100.9 | -106.3 | -99.43 | -100.5 | -99.19 | -79.67 | -75.98 |
| Operating Margin | - | - | -12,156.85% | -1,749.19% | -2,590.73% | -2,300.97% | -1,615.49% | -1,396.01% | -1,363.66% | -1,496.23% | -1,187.64% | -1,057.42% | -890.3% | -626.34% | -199.11% |
| Earnings before Tax (EBT) 1 | -84.26 | -98.58 | -94.77 | -91.81 | -81.75 | 36.53 | -81.02 | -83.81 | -91.32 | -95.94 | -91.22 | -92.67 | -58.48 | -27.16 | -67.36 |
| Net income 1 | -88.77 | -94.63 | -94.77 | -91.81 | -81.75 | 36.53 | -81.02 | -83.81 | -91.32 | -95.94 | -94.18 | -94.73 | -69.25 | -50.95 | -67.36 |
| Net margin | - | - | -11,391.11% | -1,644.68% | -2,325% | 847.47% | -1,444.43% | -1,248.6% | -1,234.27% | -1,350.7% | -1,124.89% | -996.36% | -621.6% | -400.58% | -176.51% |
| EPS 2 | -1.560 | -1.740 | -1.740 | -1.680 | -1.490 | 0.6700 | -1.470 | -1.510 | -1.640 | -1.720 | -1.647 | -1.662 | -1.244 | -0.9519 | -1.170 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-03 | 22-02-24 | 22-05-05 | 22-08-04 | 22-11-03 | 23-02-23 | 23-05-04 | 23-08-03 | 23-11-02 | 24-02-15 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 36.5 | - |
| Net Cash position 1 | 80.9 | 311 | 203 | 122 | 30.1 | 68.8 | - | 112 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -0.0893 x | - |
| Free Cash Flow 1 | -383 | -306 | -413 | -314 | -297 | -336 | -247 | -234 |
| ROE (net income / shareholders' equity) | -62% | -63% | 190% | -19.4% | -36.8% | -42.5% | -43.4% | -26.5% |
| ROA (Net income/ Total Assets) | -47% | -37.5% | 140% | -17.3% | -32.4% | -17.9% | -36.7% | -22.4% |
| Assets 1 | 874.6 | 871.8 | 1,145 | 1,338 | 1,088 | 1,778 | 983.2 | 1,340 |
| Book Value Per Share 2 | 10.70 | 5.790 | 21.40 | 20.10 | 14.60 | 12.50 | 11.40 | 9.250 |
| Cash Flow per Share 2 | - | - | -6.740 | -5.650 | -5.320 | -4.770 | -4.640 | - |
| Capex 1 | 12.2 | 14.9 | 5.74 | 4.88 | 1 | 5.27 | 6.77 | 12 |
| Capex / Sales | 10.32% | 7.34% | - | 34.28% | 3.72% | 12.47% | 5.95% | 6.05% |
| Announcement Date | 20-02-13 | 21-02-25 | 22-02-24 | 23-02-23 | 24-02-15 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
31.49
USD
Average target price
40.67
USD
Spread / Average Target
+29.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.40% | 1.77B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- AGIO Stock
- Financials Agios Pharmaceuticals, Inc.
